943750-38-7

Usage

Uses

Used in Pharmaceutical Research:
2-(4-Bromo-phenyl)-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a research compound for its potential role in the development of treatments for neurodegenerative disorders. It is valued for its ability to act as a cholinesterase inhibitor, which may contribute to improved cognitive function in patients suffering from conditions like Alzheimer's disease.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(4-Bromo-phenyl)-pyrrolidine-1-carboxylic acid tert-butyl ester is utilized as a versatile building block for the synthesis of various pharmaceutical compounds. Its structural properties allow it to be a key component in the creation of new drugs, showcasing its importance in drug discovery and development processes.

Upstream product

• 619-42-1 4-methoxycarbonylphenyl bromide 
• 1207455-72-8 tert-butyl (4-(4-bromophenyl)-4-oxobutyl)carbamate 
• 106-37-6 1.4-dibromobenzene 
• 75906-36-4 4-(p-bromophenyl)-butan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 22217-79-4 5-(4-bromophenyl)-3,4-dihydro-2H-pyrrole 
• 383127-22-8 2-(4-bromo-phenyl)-pyrrolidine 

Downstream Products

• 207989-92-2 N-t-butoxycarbonyl-γ-4-bromophenyl-γ-butyrolactam 
• 1467058-83-8 6-chloro-5-[4-(1-methylpyrrolidin-2-yl)phenyl]-1H-indole-3-carboxylic acid 
• 1467061-33-1 6-chloro-5-[4-(1-methylpyrrolidin-2-yl)phenyl]-1H-indole-3-carbaldehyde 
• 1109230-99-0 2-(4-bromophenyl)-1-methylpyrrolidine 
• 1467058-82-7 6-chloro-5-{4-[1-(methylsulfonyl)pyrrolidin-2-yl]phenyl}-1H-indole-3-carboxylic acid 
• 1467061-32-0 6-chloro-5-{4-[1-(methylsulfonyl)pyrrolidin-2-yl]phenyl}-1H-indole-3-carbaldehyde 
• 1337606-46-8 2-(4-bromophenyl)-1-(methylsulfonyl)pyrrolidine 
• 1187930-57-9 2-(4-bromophenyl)pyrrolidine hydrogen chloride 
• 1467061-30-8 tert-butyl 2-[4-(6-chloro-3-formyl-1H-indol-5-yl)phenyl]pyrrolidine-1-carboxylate 
• 1431551-94-8 tert-butyl 2-(4'-((1R,2S)-2-(2,2-dichloroacetamido)-3-fluoro-1-hydroxypropyl)-[1,1'-biphenyl]-4-yl)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

STRAD-BINDING AGENTS AND USES THEREOF

Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR

Disclosed is a type of indolo heptamyl oxime compounds as a PARP inhibitor. Specifically disclosed are a compound as represented by formula (II) and a pharmaceutically acceptable salt thereof.

A soluble iron(ii)-phthalocyanine-catalyzed intramolecular C(sp3)-H amination with alkyl azides

Herein, we describe a soluble iron(ii)-phthalocyanine, [FeII(tBu4Pc)(py)2] (Pc = phthalocyaninato(2-)), as an effective catalyst in intramolecular C(sp3)-H bond amination, with alkyl azides as the nit

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER

Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

PRC2 INHIBITORS

The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. (Formula (I))

Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition

Dysregulated translation of mRNA plays a major role in tumorigenesis. Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphoryla

PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST

The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection.

Pyrrolo pyrimidine ring compound, its use and pharmaceutical composition (by machine translation)

The invention relates to an as TLR7 agonist of the pyrrolo pyrimidine compounds, specifically on a compound of formula (I) compound or its pharmaceutically acceptable salt, preparation method thereof, containing the compounds of the pharmaceutical composition, and its use for the preparation of antiviral drug use. Formula (I) (by machine translation)